File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Monitoring and Treatment of Patients Undergoing Immunotherapy With Anti-CD20 Who are Exposed to HBV

TitleMonitoring and Treatment of Patients Undergoing Immunotherapy With Anti-CD20 Who are Exposed to HBV
Authors
Issue Date2018
PublisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/cgh
Citation
Clinical Gastroenterology and Hepatology, 2018 How to Cite?
AbstractReactivation of hepatitis B virus (HBV) is a potentially fatal complication of immunosuppressive therapy, and can occur in individuals who are hepatitis B surface antigen (HBsAg) negative but positive for hepatitis B core antibody (anti-HBc). While anti-HBc positivity indicates prior HBV exposure, it may also reflect clearance of HBsAg, but with viral persistence at low intrahepatic replicative and transcriptional levels.1 HBV reactivation can still occur during intense immunosuppression, including B cell–depleting therapy with anti-CD20 antibodies2 and hematopoietic stem cell transplantation.3 While prevention via antiviral prophylaxis is recommended, it remains uncertain, from a global perspective, if this is an ideal and cost-effective strategy. An alternative is regular HBV DNA monitoring.4 However, this approach is problematic in resource-constrained regions, where the logistics of sample collection, transportation, and molecular analysis in dedicated facilities poses challenges.5 We aimed to evaluate the effectiveness of simple monitoring strategies using routine liver biochemistry and serum HBsAg in preventing HBV-related complications during anti-CD20 therapy.
Persistent Identifierhttp://hdl.handle.net/10722/261805
ISSN
2017 Impact Factor: 7.683
2015 SCImago Journal Rankings: 2.744

 

DC FieldValueLanguage
dc.contributor.authorSeto, WKW-
dc.contributor.authorChan, SYT-
dc.contributor.authorHwang, YYG-
dc.contributor.authorMak, LY-
dc.contributor.authorWong, DKH-
dc.contributor.authorFung, JYY-
dc.contributor.authorLiu, SHK-
dc.contributor.authorCheung, KSM-
dc.contributor.authorLai, CL-
dc.contributor.authorKwong, YL-
dc.contributor.authorYuen, RMF-
dc.date.accessioned2018-09-28T04:48:25Z-
dc.date.available2018-09-28T04:48:25Z-
dc.date.issued2018-
dc.identifier.citationClinical Gastroenterology and Hepatology, 2018-
dc.identifier.issn1542-3565-
dc.identifier.urihttp://hdl.handle.net/10722/261805-
dc.description.abstractReactivation of hepatitis B virus (HBV) is a potentially fatal complication of immunosuppressive therapy, and can occur in individuals who are hepatitis B surface antigen (HBsAg) negative but positive for hepatitis B core antibody (anti-HBc). While anti-HBc positivity indicates prior HBV exposure, it may also reflect clearance of HBsAg, but with viral persistence at low intrahepatic replicative and transcriptional levels.1 HBV reactivation can still occur during intense immunosuppression, including B cell–depleting therapy with anti-CD20 antibodies2 and hematopoietic stem cell transplantation.3 While prevention via antiviral prophylaxis is recommended, it remains uncertain, from a global perspective, if this is an ideal and cost-effective strategy. An alternative is regular HBV DNA monitoring.4 However, this approach is problematic in resource-constrained regions, where the logistics of sample collection, transportation, and molecular analysis in dedicated facilities poses challenges.5 We aimed to evaluate the effectiveness of simple monitoring strategies using routine liver biochemistry and serum HBsAg in preventing HBV-related complications during anti-CD20 therapy.-
dc.languageeng-
dc.publisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/cgh-
dc.relation.ispartofClinical Gastroenterology and Hepatology-
dc.titleMonitoring and Treatment of Patients Undergoing Immunotherapy With Anti-CD20 Who are Exposed to HBV-
dc.typeArticle-
dc.identifier.emailSeto, WKW: wkseto@hku.hk-
dc.identifier.emailChan, SYT: drtchan@hku.hk-
dc.identifier.emailHwang, YYG: yyhwang@hku.hk-
dc.identifier.emailWong, DKH: danywong@hku.hk-
dc.identifier.emailFung, JYY: jfung@hkucc.hku.hk-
dc.identifier.emailLiu, SHK: drkliu@hku.hk-
dc.identifier.emailCheung, KSM: cks634@hku.hk-
dc.identifier.emailLai, CL: hrmelcl@hkucc.hku.hk-
dc.identifier.emailKwong, YL: ylkwong@hkucc.hku.hk-
dc.identifier.emailYuen, RMF: mfyuen@hku.hk-
dc.identifier.authoritySeto, WKW=rp01659-
dc.identifier.authorityWong, DKH=rp00492-
dc.identifier.authorityFung, JYY=rp00518-
dc.identifier.authorityCheung, KSM=rp02532-
dc.identifier.authorityLai, CL=rp00314-
dc.identifier.authorityKwong, YL=rp00358-
dc.identifier.authorityYuen, RMF=rp00479-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.cgh.2018.09.020-
dc.identifier.pmid30243760-
dc.identifier.hkuros293222-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats